PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 23, 2026Journal of Crohn s and Colitis0 citations

Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease Patients

P0639Real-World Effectiveness, Safety, and Dose Modifications of Upadacitinib in Patients with Crohn’s Disease: A Canadian Multicenter Study

View Full Paper
Ask AI
Bookmark
Share

Authors

LLL van LieropRDR DangTOT Omeltchenko

Discussion

Loading...

Member takes

Overview

Multicenter study assesses effectiveness and safety of upadacitinib in Crohn's disease, suggesting significant clinical benefits.

Key Points

  • This study evaluates the real-world effectiveness, safety, and dose modifications of upadacitinib in Crohn's disease patients.
  • Multicenter retrospective cohort study in Canada
  • Included patients initiating upadacitinib from 2019 to 2025
  • Primary endpoint assessed was corticosteroid-free clinical remission
  • Adverse events were documented and drug persistence analyzed
  • 55.4% achieved corticosteroid-free clinical remission by end of follow-up
  • 60.1% and 44.4% achieved clinical and biochemical remission respectively
  • 24% of patients experienced dose escalation during maintenance
  • 145 adverse events reported, with common ones including acne and infections
  • Drug persistence at year 1 was 73.9%

Cite This Study

Lierop et al. (2026) studied this question.

synapsesocial.com/papers/69730f18c8125b09b0d1ee4ehttps://doi.org/10.1093/ecco-jcc/jjaf231.820
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P0577 real world durability of response and remission with upadacitinib in Ulcerative Colitis: a multi-centre study2026
  2. 2DOP056 Efficacy and Safety of Upadacitinib After 5 Years of Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Analysis From the Phase 3 U-ACTIVATE Open-Label Extension Study2026
  3. 3P0895 Long-Term Efficacy of Upadacitinib in Patients With Moderate-to-Severe Crohn’s Disease and Prior Biologic Use2026
  4. 4P0652 Real-World Effectiveness of Upadacitinib in Patients With Moderate-to-Severe Ulcerative Colitis: Interim Findings on Treatment Patterns From the PROFUNDUS Study2026
  5. 5P1073 Real-World Effectiveness, Symptomatic Improvement, and Safety of Upadacitinib in Patients With Moderate-to-Severe Ulcerative Colitis: Interim Findings From the PROFUNDUS Study2026